Project/Area Number |
26460801
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Hygiene and public health
|
Research Institution | St. Marianna University School of Medicine (2015-2016) Kyoto University (2014) |
Principal Investigator |
Hitomi Toshiaki 聖マリアンナ医科大学, 医学部, 准教授 (90405275)
|
Co-Investigator(Kenkyū-buntansha) |
小泉 昭夫 京都大学, 医学研究科, 教授 (50124574)
小林 果 京都大学, 医学研究科, 特定講師 (70542091)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 予防医学 / もやもや病 / mysterin(RNF213) / インターフェロン / 脳血管疾患 / 血管内皮細胞 / iPS細胞 / 感染症 / Mysterin(RNF213) / R4810K / Mysterin / RNF213 / 疾患iPS細胞 |
Outline of Final Research Achievements |
Mysterin (RNF213) is a susceptibility gene for moyamoya disease (MMD) and its coding variant, p.R4810K, is a common founder variant in East Asian countries. Several angiogenic and anti-angiogenic factors [including interferons (IFNs), IFN-β and IFN-γ] induced transcriptional expression of mysterin in human umbilical vein endothelial cells (HUVECs). In HUVECs, upregulation of mysterin by IFN-β is mediated by a STAT1-binding site on the mysterin gene promoter. The anti-angiogenic activities of IFN-β are partially rescued by siRNA for STAT1, and completely rescued by siRNA for mysterin. Treatment with IFN-β induced mysterin mRNA and decreased angiogenesis in induced pluripotent stem cells-derived vascular endothelial cells (iPSECs) derived from control subjects and patients with MMD. Our data suggest that mysterin mediates the IFN-β anti-angiogenic signaling pathway; MMD may impair angiogenesis in patients with infectious or autoimmune disease.
|